

Phospho-Ser523 5-Lipoxygenase Antibody

Affinity purified rabbit polyclonal antibody Catalog # AN1074

Specification

Phospho-Ser523 5-Lipoxygenase Antibody - Product Information

Application WB
Primary Accession P09917
Reactivity Human, Rat
Predicted Monkey
Host Rabbit
Clonality polyclonal
Calculated MW 80 KDa

Phospho-Ser523 5-Lipoxygenase Antibody - Additional Information

Gene ID 240
Gene Name ALOX5

Other Names

Arachidonate 5-lipoxygenase, 5-LO, 5-lipoxygenase, ALOX5, LOG5

Target/Specificity

Synthetic phospho-peptide corresponding to amino acid residues surrounding Ser523 conjugated to KLH.

Dilution

WB~~ 1:1000

Format

Prepared from rabbit serum by affinity purification via sequential chromatography on phosphoand dephosphopeptide affinity columns.

Antibody Specificity

Specific for the ~80k 5-LO phosphorylated at Ser523 in Western blots

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

Phospho-Ser523 5-Lipoxygenase Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Shipping

Blue Ice


Phospho-Ser523 5-Lipoxygenase Antibody - Protocols



Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

Phospho-Ser523 5-Lipoxygenase Antibody - Images



Western blot of rat cortex lysate showing specific immunolabeling of the ~80k doublet of 5-LO phosphorylated at Ser523 (Control). The phosphospecificity of this labeling is shown in the second lane (lambda-phosphatase: λ -Ptase). The blot is identical to the control except that it was incubated in λ -Ptase (1200 units for 30 min) before being exposed to the 5-LO Ser523 antibody. The immunolabeling is completely eliminated by treatment with λ -Ptase.

Phospho-Ser523 5-Lipoxygenase Antibody - Background


The enzyme 5-lipoxygenase (5-LO) plays a key role in regulating the production of leukotrienes (LTs) (Funk, 2001). Overproduction of LTs contributes to several diseases, most notably chronic inflammatory diseases, including asthma (Drazen et al., 1994), fibrosis (Wilborn et al., 1996) and atherosclerosis (Dwyer et al., 2004). Recent work has demonstrated that the activity of 5-LO is regulated by PKA phosphorylation of serine-523 in 5-LO (Luo et al., 2004). Under normal conditions, this phosphorylation may be important in limiting inflammation. Abnormal signaling through cAMP and PKA, then, could contribute to a variety of diseases, including those characterized by chronic inflammation. The phospho-specific antibody to Ser523 on 5-LO is thus likely to provide a valuable tool for studies of the role of 5-LO regulation in diseases such as asthma, fibrosis and atherosclerosis

Phospho-Ser523 5-Lipoxygenase Antibody - References

Drazen JM, Lilly CM, Sperling R, Rubin P, Israel E (1994) Role of cysteinyl leukotrienes in spontaneous asthmatic responses. Adv. Prostaglandin Thromboxane Leukot Res 22:251-262. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, Lusis AJ, Mehrabian M (2004) Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. New England J Med 350:29-37.

Funk, CD (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294:1871-1875.

Luo M, Jones SM, Phare SM, Coffey MJ, Peters-Golden M, Brock TG (2004) Protein kinase A inhibits





leukotriene synthesis by phosphorylation of 5-lipoxygenase on Serine 523. J Biol Chem 279:41,512-41,520.

Wilborn J, Bailie M, Coffey M, Burdick M, Strieter R, Peters-Golden M. (1996) Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 97:1827-1836.

Luo M, Jones SM, Phare SM, Coffey MJ, Peters-Golden M, Brock TG.(2004) Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523. J Biol Chem. 279(40):41512-20. Epub 2004 Jul 26.